For some patients, weight regain despite intensive lifestyle efforts may warrant consideration of resuming tirzepatide or transitioning to alternative anti-obesity medications, provided they meet FDA-indicated criteria (BMI 30 kg/m or 27 kg/m with weight-related comorbidity)
Its important to consult a healthcare provider to determine if its right for you
The 12 mg dose in TRIUMPH-4 led to a 28.7% loss over 68 weeks, while tirzepatide in the SURMOUNT-1 trial produced approximately 22.5% loss over 72 weeks
evaluated retatrutide a once-weekly injectable agent targeting GLP-1, GIP, and glucagon receptors simultaneously across multiple doses in adults with obesity or overweight without type 2 diabetes
WADA Prohibition Status Based on WADAs prohibition categories: GLP3 likely falls under Section S0 (Non-Approved Substances) of the WADA Prohibited List, which includes: Any pharmacological substance not approved by governmental regulatory health authorities for human therapeutic use Drugs under preclinical or clinical development Substances without current regulatory approval from any health authority worldwide Implications for competitive athletes: Prohibited at all times (in-competition and out-of-competition) No Therapeutic Use Exemptions available for unapproved substances Use could result in anti-doping rule violations and sanctions Detection methods under development as clinical trials progress Research Classification: GLP3 is available exclusively for use in FDA-approved clinical trials under Investigational New Drug applications
That's an average of 71.2 pounds lost
